U.S. markets closed
  • S&P Futures

    4,636.00
    +40.25 (+0.88%)
     
  • Dow Futures

    35,083.00
    +225.00 (+0.65%)
     
  • Nasdaq Futures

    16,231.50
    +180.50 (+1.12%)
     
  • Russell 2000 Futures

    2,264.50
    +21.20 (+0.95%)
     
  • Crude Oil

    71.64
    +3.49 (+5.12%)
     
  • Gold

    1,798.20
    +10.10 (+0.56%)
     
  • Silver

    23.45
    +0.32 (+1.38%)
     
  • EUR/USD

    1.1284
    -0.0036 (-0.32%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • Vix

    28.62
    +10.04 (+54.04%)
     
  • GBP/USD

    1.3337
    -0.0002 (-0.01%)
     
  • USD/JPY

    113.6100
    +0.3000 (+0.26%)
     
  • BTC-USD

    57,250.39
    +2,973.64 (+5.48%)
     
  • CMC Crypto 200

    1,427.90
    -27.51 (-1.89%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,746.49
    -5.13 (-0.02%)
     

FUV, ACAD & EBS Approaching Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Lead Plaintiff Deadlines: June 18, 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Arcimoto, Inc. (NASDAQ:FUV)
Class Period: February 14, 2018 - March 22, 2021
Deadline: June 18, 2021
For more info: www.bgandg.com/fuv.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the preorders of Arcimoto's Fun Utility Vehicles ("FUVs") were fabricated or never completed, with only 19 units delivered out of an alleged preorder of 422; (2) Arcimoto failed to disclose to customers that nearly 100% of its vehicles delivered were under safety recall; (3) Arcimoto's largest customer, R-Key-Moto, was an undisclosed related party owned by insider FOD Capital, LLC; (4) Arcimoto's partnership with HULA was an undisclosed related party transaction; and (5) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Class Period: June 15, 2020 - April 4, 2021
Deadline: June 18, 2021
For more info: www.bgandg.com/acad.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (2) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (3) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

Emergent BioSolutions Inc. (NYSE:EBS)
Class Period: July 6, 2020 - March 31, 2021
Deadline: June 18, 2021
For more info: www.bgandg.com/ebs

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Emergent BioSolution's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) these longstanding contamination risks and quality control issues at Emergent BioSolution's facility led to a string of FDA citations; (3) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (4) as a result of the foregoing, defendants' public statements about Emergent BioSolution's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/650238/FUV-ACAD-EBS-Approaching-Deadlines-Bronstein-Gewirtz-Grossman-LLC-Reminds-Investors-of-Class-Actions-and-Lead-Plaintiff-Deadlines-June-18-2021